|Bid||2.6400 x 3200|
|Ask||2.6400 x 1800|
|Day's Range||2.4100 - 2.7214|
|52 Week Range||1.5825 - 65.0000|
|Beta (5Y Monthly)||4.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CELZLearn more
Creative Medical Technology, a small Phoenix biotech company, recently moved from the OTC Market to the Nasdaq. Public filings shed light on the company's tough financial picture and plans for the future.
(OTC-CELZ) Creative Medical Technology Holdings, Inc. (the "Company"), a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications, today announced its intention to effect a 1-for-500 reverse split of its common stock in preparation for a planned listing of the Company's securities on The Nasdaq Capital Market ("Nasdaq"). The reverse stock s
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today proof of concept data demonstrating the ability of its next generation ImmCelz™ immunotherapy product to "reprogram" patient immune cells using the Company's patent pending "ex vivo cell-free" reprogramming protocol.